Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Anthranilide anticoagulants developed by Schering AG researchers

July 29, 1999

Antiplatelet agents acting as IP receptor agonists developed at Fujisawa

July 23, 1999

Brain '99: lanoteplase improves microcirculation in ischemic brain

July 22, 1999

Wide series of factor Xa inhibitors specifically claimed by DuPont

July 20, 1999

New coagulation factor inhibitors under study at Merck KGaA

July 16, 1999

Hoechst Marion Roussel files for new indication of Refludan in U.S. and E.U.

July 15, 1999

Hyseq presents therapeutic candidate for reducing blood clotting

July 15, 1999

Avigen licenses AAV-factor IX technology from the Children's Hospital of Philadelphia

July 14, 1999

Teijin patents novel and clinically useful factor Xa inhibitors

July 9, 1999

Emisphere and Elan restructure joint venture for development and marketing of oral heparin

July 9, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...